This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Genetic Basis for Vulnerability to Substance Abuse

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: October 31, 2005
Last updated: January 11, 2017
Last verified: October 2005
This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Condition Intervention
Substance Abuse Procedure: Blood draw

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Allelic Linkage in Substance Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 8000
Study Start Date: August 1992
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study.

This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Substance abusers
  • Allow for blood draw

Exclusion Criteria:

  • Cognitively impaired
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00247819

United States, Maryland
National Institute on Drug Abuse
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: George Uhl, M.D., Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.
Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534. Identifier: NCT00247819     History of Changes
Other Study ID Numbers: NIDA-IRP-148
Study First Received: October 31, 2005
Last Updated: January 11, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
Substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on September 21, 2017